載入...
Bromocriptine in type 2 diabetes mellitus
Bromocriptine mesylate quick-release was approved by the Food and Drug Administration (FDA) in May 2009, for the treatment of type 2 diabetes. Bromocriptine is thought to act on the circadian neuronal activities in the hypothalamus, to reset an abnormally elevated hypothalamic drive for increased pl...
Na minha lista:
| Main Authors: | , |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Medknow Publications
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3152192/ https://ncbi.nlm.nih.gov/pubmed/21847449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4103/2230-8210.83058 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|